Healthesystems is attending the New York Self-Insurers Association Annual Meeting, a forum to discuss issues relating to self-insurance.
Healthesystems is attending the Workers Compensation Research Institute Issues & Research Conference for senior-level decision makers from across the workers' compensation spectrum.
Approval Date: Jan 2025
A novel, first-in-class, non-opioid analgesic indicated for the treatment of moderate to severe acute pain. Journavx targets pain-signaling pathways involving sodium channels and has not been studied for use beyond 14 days
Approval Date: Dec 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the once-daily treatment of type 2 diabetes, in conjunction with diet and exercise
Approval Date: Dec 2024
A biosimilar to Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis
Approval Date: Dec 2024
An SSRI indicated for the treatment of major depressive disorder (MDD)
Approval Date: Nov 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the treatment of type 2 diabetes, in conjunction with diet and exercise
Approval Date: Sep 2024
A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis
Approval Date: Aug 2024
Indicated for the treatment of opioid-induced constipation
Approval Date: Aug 2024
An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.
Approval Date: Aug 2024
Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults
Approval Date: Aug 2024
Indicated for the emergency treatment of type I allergic reactions, including anaphylaxis
